<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841281</url>
  </required_header>
  <id_info>
    <org_study_id>271515</org_study_id>
    <secondary_id>R01HL105573</secondary_id>
    <secondary_id>UCD105573</secondary_id>
    <nct_id>NCT01841281</nct_id>
  </id_info>
  <brief_title>L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels</brief_title>
  <official_title>Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Kenyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major impact of this study will be to identify the adult severe asthma cohort that will
      benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of
      adult severe asthma patients will respond to supplemental L-arginine and derive clinical
      benefit from the addition of this therapy to standard-of-care asthma medications. The
      investigators hypothesize that the patients that benefit most will have low exhaled nitric
      oxide concentrations (&lt; 20 ppb) at baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that a subset of adult severe asthma patients will respond to supplemental
      L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care
      medications. We hypothesize that these patients will have lower exhaled NO concentrations
      (&lt;20 ppb) and lower nitric oxide synthase 2 (NOS2)/ arginase I (Arg1) mRNA ratios in their
      airway epithelial cells than &quot;non-responders.&quot; The aim is to test the hypothesis that adult
      severe asthma subjects with exhaled breath NO concentrations &lt; 20 ppb will have fewer
      American Thoracic Society (ATS)-defined asthma exacerbations over 3 months when treated with
      L-arginine compared to subjects with exhaled nitric oxide concentration (FeNO) &gt; 25 ppb. The
      major impact of this study will be to identify the adult severe asthma cohort that will
      benefit from supplemental L-arginine therapy to define the underlying mechanisms of arginine
      benefit in asthma. This follows our initial 20 subject trial of L-arginine in asthma subjects
      (Kenyon et al., Pharmaceuticals 2011) that was designed to determine how L-arginine was
      metabolized (by testing serum markers) and whether certain participants had clinical benefit.

      To do this, we will recruit a total of 50 ATS-defined severe asthmatic subjects with ongoing
      asthma exacerbations in past two months and enroll them in a randomized, blinded,
      placebo-controlled, cross-over designed trial of L-arginine and placebo. We will compare 25
      subjects with &quot;low&quot; FeNO &lt; 20 with 25 subjects that have &quot;high&quot; FeNO &gt; 25 ppb.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Acute Exacerbation at 3 Months</measure>
    <time_frame>3 month</time_frame>
    <description>The primary endpoint of the study is the number of acute moderate exacerbations at 3 months. A moderate asthma exacerbation is defined as any of the following: 1) A drop in morning peak flow rate (PEFR) &gt;30% from baseline on 2 consecutive days (1 event), 2) Need for initiation of oral steroids or am increased dose of inhaled corticosteroids on any two consecutive days (1 event), 3) Doubling of short-acting Î²-agonist use (e.g. number of puffs of albuterol) per day for 2 consecutive days (1 event).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)</measure>
    <time_frame>3 month</time_frame>
    <description>The secondary endpoint is the change in FEV1/FVC ratio at 3 months. This calcuation is a ratio between the volume of breath exhaled in the first second divided by the total amount of breath exhaled in a vital capacity maneuver. A normal ratio is usually &gt; 70%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Asthma</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Low Exhaled Nitric Oxide (NO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.
All subjects will receive L-arginine and placebo in this cross-over design study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Exhaled Nitric Oxide (NO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.
All subjects will receive L-arginine and placebo in this cross-over design study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Arginine</intervention_name>
    <description>L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.</description>
    <arm_group_label>High Exhaled Nitric Oxide (NO)</arm_group_label>
    <arm_group_label>Low Exhaled Nitric Oxide (NO)</arm_group_label>
    <other_name>Arginine 1000 (Jarrow Formulas, Los Angeles, CA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
    <arm_group_label>High Exhaled Nitric Oxide (NO)</arm_group_label>
    <arm_group_label>Low Exhaled Nitric Oxide (NO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;18 yrs of age

          -  Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am
             J Respir Crit Care Med 2000; 162:2341)

          -  Active asthma medications of high dose inhaled corticosteroids plus long-acting beta
             agonist

          -  History of recent asthma exacerbations or Asthma control test score &lt; 20/25

        Exclusion Criteria:

          -  &lt;19 yrs of age

          -  Forced expiratory volume 1sec &lt;30% predicted

          -  Pregnant or nursing women

          -  Current smokers or smoking history &gt; 15 pack years

          -  Actively taking or known intolerance to L-arginine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Kenyon, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis CTSC Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>April 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2020</results_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Nicholas Kenyon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Severe Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01841281/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>54 subjects consented and enrolled for the trial, but n=50 were randomized as n=4 participants declined to participate.</recruitment_details>
      <pre_assignment_details>Participants were assigned to low or high exhaled nitric oxide groups based on their levels at time of Visit 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
          <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
        </group>
        <group group_id="P2">
          <title>High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
          <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
        </group>
        <group group_id="P3">
          <title>Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
          <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive Placebo first, then L-arginine
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
        </group>
        <group group_id="P4">
          <title>High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
          <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Exhaled Nitric Oxide (NO)</title>
          <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.
Baseline characteristics at the enrollment</description>
        </group>
        <group group_id="B2">
          <title>High Exhaled Nitric Oxide (NO)</title>
          <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.
Baseline characteristics at the enrollment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="11.9"/>
                    <measurement group_id="B2" value="52.4" spread="14.3"/>
                    <measurement group_id="B3" value="54.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spirometry</title>
          <units>Litters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.7"/>
                    <measurement group_id="B2" value="2.2" spread="0.9"/>
                    <measurement group_id="B3" value="2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="0.9"/>
                    <measurement group_id="B2" value="2.8" spread="1.1"/>
                    <measurement group_id="B3" value="2.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.8" spread="20.5"/>
                    <measurement group_id="B2" value="85.6" spread="27.3"/>
                    <measurement group_id="B3" value="90.0" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test Score</title>
          <description>The total Asthma Control Test score is reported. It is on a scale of 5 to 25. The higher the score, the better the asthma control. A score of 20 or more suggests good asthma control. A score of less than 20 suggests inadequate asthma control.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="4.6"/>
                    <measurement group_id="B2" value="16.1" spread="5.5"/>
                    <measurement group_id="B3" value="16.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Acute Exacerbation at 3 Months</title>
        <description>The primary endpoint of the study is the number of acute moderate exacerbations at 3 months. A moderate asthma exacerbation is defined as any of the following: 1) A drop in morning peak flow rate (PEFR) &gt;30% from baseline on 2 consecutive days (1 event), 2) Need for initiation of oral steroids or am increased dose of inhaled corticosteroids on any two consecutive days (1 event), 3) Doubling of short-acting Î²-agonist use (e.g. number of puffs of albuterol) per day for 2 consecutive days (1 event).</description>
        <time_frame>3 month</time_frame>
        <population>Several patients dropped after the first intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
            <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O2">
            <title>High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
            <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O3">
            <title>Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
            <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive Placebo first, then L-arginine
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O4">
            <title>High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
            <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Exacerbation at 3 Months</title>
          <description>The primary endpoint of the study is the number of acute moderate exacerbations at 3 months. A moderate asthma exacerbation is defined as any of the following: 1) A drop in morning peak flow rate (PEFR) &gt;30% from baseline on 2 consecutive days (1 event), 2) Need for initiation of oral steroids or am increased dose of inhaled corticosteroids on any two consecutive days (1 event), 3) Doubling of short-acting Î²-agonist use (e.g. number of puffs of albuterol) per day for 2 consecutive days (1 event).</description>
          <population>Several patients dropped after the first intervention</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.0"/>
                    <measurement group_id="O2" value="2.2" spread="2.2"/>
                    <measurement group_id="O3" value="1.6" spread="1.8"/>
                    <measurement group_id="O4" value="2.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.4"/>
                    <measurement group_id="O2" value="2.7" spread="4.2"/>
                    <measurement group_id="O3" value="2.2" spread="2.2"/>
                    <measurement group_id="O4" value="2.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>The p-value is for the interaction term</p_value_desc>
            <method>testing for interaction term</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)</title>
        <description>The secondary endpoint is the change in FEV1/FVC ratio at 3 months. This calcuation is a ratio between the volume of breath exhaled in the first second divided by the total amount of breath exhaled in a vital capacity maneuver. A normal ratio is usually &gt; 70%.</description>
        <time_frame>3 month</time_frame>
        <population>Several patients dropped after the first intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
            <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O2">
            <title>High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo</title>
            <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O3">
            <title>Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
            <description>Subjects with a baseline exhaled NO level less than or equal to 20 ppb
Receive Placebo first, then L-arginine
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
          <group group_id="O4">
            <title>High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine</title>
            <description>Subjects with a baseline exhaled NO level greater than or equal to 25 ppb
Receive L-arginine first, then Placebo
L-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
Placebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)</title>
          <description>The secondary endpoint is the change in FEV1/FVC ratio at 3 months. This calcuation is a ratio between the volume of breath exhaled in the first second divided by the total amount of breath exhaled in a vital capacity maneuver. A normal ratio is usually &gt; 70%.</description>
          <population>Several patients dropped after the first intervention</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.05"/>
                    <measurement group_id="O2" value="0.01" spread="0.06"/>
                    <measurement group_id="O3" value="0.03" spread="0.13"/>
                    <measurement group_id="O4" value="-0.03" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.04"/>
                    <measurement group_id="O2" value="0.13" spread="0.06"/>
                    <measurement group_id="O3" value="0.003" spread="0.06"/>
                    <measurement group_id="O4" value="-0.04" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The treatment effect was tested as an interaction term between treatment and FeNO. The null hypothesis is the effect of treatment is stratified by the FeNO status. We used a regression model instead of t-test or Wilcoxon signed-rank test in order to control period and carry-over effect which is common in a cross-over study design</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>The p-value is for the interaction term</p_value_desc>
            <method>testing for interaction term</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the trial,8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Exhaled Nitric Oxide (NO) Phase 1, Treatment Arm</title>
          <description>ow Exhaled Nitric Oxide (NO) Phase 1, L-Arginine arm</description>
        </group>
        <group group_id="E2">
          <title>Low Exhaled Nitric Oxide (NO) Phase 1, Placebo Arm</title>
          <description>Low Exhaled Nitric Oxide (NO) Phase 1, placebo arm</description>
        </group>
        <group group_id="E3">
          <title>Low Exhaled Nitric Oxide (NO) Washout Phase</title>
          <description>Low Exhaled Nitric Oxide (NO) Washout Phase</description>
        </group>
        <group group_id="E4">
          <title>Low Exhaled Nitric Oxide (NO) Phase 2, Treatment Arm</title>
          <description>Low Exhaled Nitric Oxide (NO) Phase 2, L-Arginine arm</description>
        </group>
        <group group_id="E5">
          <title>Low Exhaled Nitric Oxide (NO) Phase 2, Placebo Arm</title>
          <description>Low Exhaled Nitric Oxide (NO) Phase 2, placebo arm</description>
        </group>
        <group group_id="E6">
          <title>High Exhaled Nitric Oxide (NO) Phase 1, Treatment Arm</title>
          <description>High Exhaled Nitric Oxide (NO) Phase 1, L-Arginine arm</description>
        </group>
        <group group_id="E7">
          <title>High Exhaled Nitric Oxide (NO) Phase 1, Placebo Arm</title>
          <description>High Exhaled Nitric Oxide (NO) Phase 1, placebo arm</description>
        </group>
        <group group_id="E8">
          <title>High Exhaled Nitric Oxide (NO) Washout Phase</title>
          <description>High Exhaled Nitric Oxide (NO) Washout Phase</description>
        </group>
        <group group_id="E9">
          <title>High Exhaled Nitric Oxide (NO) Phase 2, Treatment Arm</title>
          <description>High Exhaled Nitric Oxide (NO) Phase 2, L-Arginine arm</description>
        </group>
        <group group_id="E10">
          <title>High Exhaled Nitric Oxide (NO) Phase 2, Placebo Arm</title>
          <description>igh Exhaled Nitric Oxide (NO) Phase 2, Placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Subject was admitted to the hospital for exacerbation or flare of asthma either on placebo or L-arginine.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nicholas Kenyon</name_or_title>
      <organization>UC Davis</organization>
      <phone>916-734-3564</phone>
      <email>njkenyon@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

